摘要
目的:分析国家药品集中带量采购及接续政策对药品用量、价格及费用的影响,为进一步优化国家药品集中带量采购政策提供建议。方法:运用描述性统计方法,通过用药频度、药品采购金额、药品日均费用、仿制药数量替代率、仿制药金额替代率和年复合增长率6个指标,统计分析4个直辖市国家药品集中带量采购及接续政策实施前后医院和药店渠道下国家药品集中带量采购的执行效果。结果:国家药品集中带量采购基本实现招采合一、降低药价、促进仿制药替代等目标。然而,原研药向药店端转移的趋势,表明了患者对过评仿制药信任度相对不足的现状。结论:进一步厘清国家药品集中带量采购接续政策与医保支付标准制定之间的关系,强化中选品种在真实世界中的疗效与安全性评估,加强过评仿制药的宣传,提升公众认知与接受度。
It aims to evaluate the impact of National Phamaceutical Centralized Purchase(NPCP)and continuation policies on drug utilization,pricing,and expenditure,providing insights for optimizing national procurement strategies.Methods:Using descriptive statistics,a statistical analysis was conducted to examine changes in drug procurement amounts,Defined Daily Doses(DDDs),Defined Daily Dose cost(DDDc),and generic drug substitution rates pre-and post-implementation of the NPCP and continuation policies in hospitals and pharmacies across four municipalities.Results:The policy successfully achieved its goals of streamlining procurement processes,reducing drug prices,and promoting generic drug substitution.However,a notable trend of originator drug diversion to the retail sector was observed,indicating lingering patient reservations towards generics.Conclusion:It is needed to clarty the relation ship between NPCP continous policy and the medical insurance payment standard decision,strengthen the real-world evaluation on selected drug efficacy and safety,enhance the publicity on rated generic drugs,and promote the acceptance of public awareness.
作者
王浩扬
韩悦
谢金平
邵蓉
Wang Haoyang;Han Yue;Xie Jinping(Institute of Regulatory Science for Medical Products,China Pharmaceutical University,Nanjing,Jiangsu,211198,China;不详)
出处
《中国卫生经济》
北大核心
2024年第10期31-37,共7页
Chinese Health Economics
关键词
药品集中带量采购
采购政策
药品价格及费用
仿制药
原研药
pharmaceutical centralized purchase
purchasing policy
drug price and cost
generic drugs
originator drug